A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants with HIV-1 Virologically Suppressed on Biktarvy By midwayadmin|2020-11-03T20:00:39+00:00May 15th, 2020| Read More
A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in participants with HIV-1 Virologically Suppressed on Antiretroviral Therapy (ART). By midwayadmin|2020-11-03T20:01:11+00:00May 15th, 2020| Read More
A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects By midwayadmin|2019-10-28T19:40:05+00:00October 28th, 2019| Read More
Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis By midwayadmin|2019-10-28T19:37:43+00:00October 28th, 2019| Read More
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I By midwayadmin|2019-10-28T19:36:55+00:00October 28th, 2019| Read More
Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated HIV-1 Infected Controllers By midwayadmin|2019-10-28T19:35:43+00:00October 28th, 2019| Read More
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL) By midwayadmin|2019-10-28T19:34:34+00:00October 28th, 2019| Read More
A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects By midwayadmin|2019-10-28T19:33:02+00:00October 28th, 2019| Read More
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients By midwayadmin|2019-10-28T19:31:48+00:00October 28th, 2019| Read More
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants By midwayadmin|2019-10-28T19:30:22+00:00October 28th, 2019| Read More
